Advertisement
Screener

MANNKIND CORP (MNKD) Construction in Progress Expenditures Incurred but Not yet Paid

2.9 / 5 stars · 48/83 Roast Me

MANNKIND CORP Construction in Progress Expenditures Incurred but Not yet Paid

MANNKIND CORP (MNKD) reported Construction in Progress Expenditures Incurred but Not yet Paid of $588.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-26.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:ConstructionInProgressExpendituresIncurredButNotYetPaid · last filed 2019-02-26

  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for the quarter ending 2016-03-31 was $558.00K, a 48.99% decline year-over-year.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for the quarter ending 2015-09-30 was -$431.00K, a 151.07% decline year-over-year.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for the quarter ending 2015-06-30 was -$471.00K, a 137.23% decline year-over-year.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for the quarter ending 2015-03-31 was $1.09M, a 35.65% decline year-over-year.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for fiscal 2016 was $588.00K.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for fiscal 2014 was $1.77M, a 106.54% increase from fiscal 2013.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for fiscal 2013 was $856.00K, a 78.98% decline from fiscal 2012.
  • MANNKIND CORP construction in progress expenditures incurred but not yet paid for fiscal 2012 was $4.07M, a 1528.80% increase from fiscal 2011.
Period endConstruction in Progress Expenditures Incurred but Not yet Paid 3 monthConstruction in Progress Expenditures Incurred but Not yet Paid 6 monthConstruction in Progress Expenditures Incurred but Not yet Paid 9 monthConstruction in Progress Expenditures Incurred but Not yet Paid 12 monthConstruction in Progress Expenditures Incurred but Not yet Paid 244 monthConstruction in Progress Expenditures Incurred but Not yet Paid 247 monthConstruction in Progress Expenditures Incurred but Not yet Paid 250 monthConstruction in Progress Expenditures Incurred but Not yet Paid 253 monthConstruction in Progress Expenditures Incurred but Not yet Paid 256 monthConstruction in Progress Expenditures Incurred but Not yet Paid 259 monthConstruction in Progress Expenditures Incurred but Not yet Paid 263 monthConstruction in Progress Expenditures Incurred but Not yet Paid 265 monthConstruction in Progress Expenditures Incurred but Not yet Paid 268 monthConstruction in Progress Expenditures Incurred but Not yet Paid 271 monthConstruction in Progress Expenditures Incurred but Not yet Paid 275 monthConstruction in Progress Expenditures Incurred but Not yet Paid 277 monthConstruction in Progress Expenditures Incurred but Not yet Paid 280 monthConstruction in Progress Expenditures Incurred but Not yet Paid 283 month
2016-12-31$588.00K
10-K · filed 2019-02-26
2016-03-31$558.00K
10-Q · filed 2017-05-10
2015-09-30-$431.00K
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2016-11-09
-$902.00K
derived: sum of 2 quarters · filed 2016-11-09
$192.00K
10-Q · filed 2016-11-09
-$1.85M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30-$471.00K
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10
$623.00K
10-Q/A · filed 2016-08-10
-$1.42M
derived: sum of 3 quarters · filed 2017-03-16
-$574.00K
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$1.09M
10-Q · filed 2016-05-09
-$947.00K
derived: sum of 2 quarters · filed 2017-03-16
-$103.00K
derived: sum of 3 quarters · filed 2017-03-16
$1.16M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31-$2.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
-$1.20M
derived: sum of 2 quarters · filed 2017-03-16
$68.00K
derived: sum of 3 quarters · filed 2017-03-16
$1.77M
10-K · filed 2017-03-16
2014-09-30$844.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
$2.11M
derived: sum of 2 quarters · filed 2015-11-09
$3.81M
10-Q · filed 2015-11-09
-$858.00K
derived: sum of 4 quarters · filed 2016-03-15
$3.09M
10-Q · filed 2014-11-10
2014-06-30$1.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
$2.96M
10-Q · filed 2015-08-10
-$1.70M
derived: sum of 3 quarters · filed 2016-03-15
-$784.00K
derived: sum of 4 quarters · filed 2016-03-15
$2.96M
10-Q · filed 2014-08-11
2014-03-31$1.70M
10-Q · filed 2015-05-11
-$2.97M
derived: sum of 2 quarters · filed 2016-03-15
-$2.05M
derived: sum of 3 quarters · filed 2016-03-15
-$1.31M
derived: sum of 4 quarters · filed 2016-03-15
$1.70M
10-Q · filed 2014-05-12
2013-12-31-$4.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
-$3.75M
derived: sum of 2 quarters · filed 2016-03-15
-$3.01M
derived: sum of 3 quarters · filed 2016-03-15
$856.00K
10-K · filed 2016-03-15
$856.00K
10-K · filed 2014-03-03
2013-09-30$918.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
$1.66M
derived: sum of 2 quarters · filed 2014-11-10
$5.52M
10-Q · filed 2014-11-10
$6.69M
derived: sum of 4 quarters · filed 2015-03-02
$5.52M
10-Q · filed 2013-11-12
2013-06-30$742.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11
$4.61M
10-Q · filed 2014-08-11
$5.77M
derived: sum of 3 quarters · filed 2015-03-02
$6.33M
derived: sum of 4 quarters · filed 2015-03-02
$4.61M
10-Q · filed 2013-08-09
2013-03-31$3.86M
10-Q · filed 2014-05-12
$5.03M
derived: sum of 2 quarters · filed 2015-03-02
$5.59M
derived: sum of 3 quarters · filed 2015-03-02
$7.01M
derived: sum of 4 quarters · filed 2015-03-02
$3.86M
10-Q · filed 2013-05-10
2012-12-31$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$1.73M
derived: sum of 2 quarters · filed 2015-03-02
$3.15M
derived: sum of 3 quarters · filed 2015-03-02
$4.07M
10-K · filed 2015-03-02
$4.07M
10-K · filed 2013-03-18
2012-09-30$564.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$1.99M
derived: sum of 2 quarters · filed 2013-11-12
$2.91M
10-Q · filed 2013-11-12
$2.98M
derived: sum of 4 quarters · filed 2014-03-03
$2.91M
10-Q · filed 2012-11-09
2012-06-30$1.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
$2.34M
10-Q · filed 2013-08-09
$2.41M
derived: sum of 3 quarters · filed 2014-03-03
$1.55M
derived: sum of 4 quarters · filed 2014-03-03
$2.34M
10-Q · filed 2012-08-09
2012-03-31$921.00K
10-Q · filed 2013-05-10
$990.00K
derived: sum of 2 quarters · filed 2014-03-03
$132.00K
derived: sum of 3 quarters · filed 2014-03-03
-$3.15M
derived: sum of 4 quarters · filed 2014-03-03
$921.00K
10-Q · filed 2012-05-10
2011-12-31$69.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
-$789.00K
derived: sum of 2 quarters · filed 2014-03-03
-$4.07M
derived: sum of 3 quarters · filed 2014-03-03
$250.00K
10-K · filed 2014-03-03
$250.00K
10-K · filed 2012-03-15
2011-09-30-$858.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
-$4.14M
derived: sum of 2 quarters · filed 2012-11-09
$181.00K
10-Q · filed 2012-11-09
$460.00K
derived: sum of 4 quarters · filed 2013-03-18
$181.00K
10-Q · filed 2011-11-04
2011-06-30-$3.28M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$1.04M
10-Q · filed 2012-08-09
$1.32M
derived: sum of 3 quarters · filed 2013-03-18
$2.32M
derived: sum of 4 quarters · filed 2013-03-18
$1.04M
10-Q · filed 2011-08-04
2011-03-31$4.32M
10-Q · filed 2012-05-10
$4.60M
derived: sum of 2 quarters · filed 2013-03-18
$5.60M
derived: sum of 3 quarters · filed 2013-03-18
2010-12-31$279.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$1.28M
derived: sum of 2 quarters · filed 2013-03-18
$1.74M
10-K · filed 2013-03-18
2010-09-30$1.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04
$1.46M
10-Q · filed 2011-11-04
2010-06-30$459.00K
10-Q · filed 2011-08-04
2009-12-31$620.00K
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19